Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix

  • Ru MA ,
  • Xin-bao LI ,
  • Feng-cai YAN ,
  • Yu-lin LIN ,
  • Yan LI
Expand
  • 1. Department of Peritoneal Cancer Surgery, Beijing 100038, China
    2. Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

Received date: 2019-12-09

  Online published: 2020-04-18

Supported by

Supported by Beijing Municipal Administration of Hospitals' Ascent Plan(DFL20180701);Special Fund for the Capital Characteristic Clinical Medicine Development Project(Z161100000516077);Beijing Municipal Grant for Medical Talents Group on Peritoneal Surface Oncology(2017400003235J007);Beijing Natural Science Foundation(7172108);Beijing Natural Science Foundation(2018-TG-27);Beijing Natural Science Foundation(7172108);Health Science Promotion Project of Beijing(2018-TG-27)

Abstract

Objective: To evaluate the effect of tumor-stroma ratio (TSR) on disease progression and prognosis of pseudomyxoma peritonei (PMP) from the appendix.Methods: The study included 30 PMP patients with complete individual patient data, who underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Beijing Shijitan Hospital. Image-Pro Plus was used to quantitatively analyze the proportion of tumor and stromal areas in hematoxylin-eosin staining pathological images, from which TSR was derived. Correlation studies were conducted to evaluate the relationships between TSR and clinicopathological features, immunohistochemical characteristics, and prognosis of PMP.Results: Among 30 PMP patients, there were 16 males (53.3%) and 14 females (46.7%), with the mean age of (54.9±2.3) years. There were 15 cases (50.0%) of low-grade mucinous carcinoma peritonei (LMCP) and high-grade mucinous carcinoma peritonei (HMCP), respectively, with vascular tumor emboli occurring in 4 cases (13.3%), nerve invasion occurring in 3 cases (10.0%), and lymphatic metastasis occurring in 4 cases (13.3%). The median peritoneal cancer index (PCI) score was 36 (range: 3-39). The median TSR was 8% (range: 2%-24%), with TSR≤10% in 19 cases (63.3%) and TSR>10% in 11 cases (36.7%). Immunohistochemistry showed that 16 cases (53.3%) had Ki67 label index ≤ 50% and 14 cases (46.7%) > 50%. The mutation rate of p53 was 56.7% and the loss rate of MMR protein was 11.8%. In addition, the expression rates of MUC2, MUC5AC, CDX2, CK7, and CK20 were 66.7%, 100.0%, 82.6%, 56.0%, and 92.3%, respectively. There were significant correlations between TSR and histopathological types, nerve invasion, Ki67 label index, and p53 mutation (P<0.05 for all). At the end of the last follow-up, 21 patients (70.0%) died and 9 patients (30.0%) survived, including 6 patients survived with tumor. The median overall survival (OS) was 12.7 months (95%CI: 10.4-11.5 months), and the 1-, 2-, and 3-year survival rates were 60.5%, 32.3%, and 27.7%, respectively. The median OS was 19.4 months (95%CI: 3.0-35.9 months) in the TSR≤10% group, versus 12.6 months (95%CI: 0.7-24.5 months) in the TSR>10% group (χ 2=3.996, P=0.046).Conclusion: TSR is correlated with histopathological types, tumor proliferation, invasion behaviors and prognosis of PMP, thus could be a new prognostic indicator for PMP.

Cite this article

Ru MA , Xin-bao LI , Feng-cai YAN , Yu-lin LIN , Yan LI . Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix[J]. Journal of Peking University(Health Sciences), 2020 , 52(2) : 240 -246 . DOI: 10.19723/j.issn.1671-167X.2020.02.008

References

[1] 李雁, 许洪斌, 彭正 , 等. 肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜假黏液瘤专家共识[J]. 中华医学杂志, 2019,99(20):1527-1535.
[2] Carr NJ, Cecil TD, Mohamed F , et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: The results of the peritoneal surface oncology group international (psogi) modified delphi process[J]. Am J Surg Pathol, 2016,40(1):14-26.
[3] 李鑫宝, 林育林, 姬忠贺 , 等. 肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜假黏液瘤182例分析[J]. 中国肿瘤临床, 2018,45(18):943-949.
[4] Mohamed F, Gething S, Haiba M , et al. Clinically aggressive pseudomyxoma peritonei: A variant of a histologically indolent process[J]. J Surg Oncol, 2004,86(1):10-15.
[5] 蔡浩, 刘江伟, 黄建钊 . 肿瘤间质比在恶性肿瘤预后评估中的应用研究进展[J]. 山东医药, 2017,57(27):112-114.
[6] 闫风彩, 林育林, 赵洪禹 , 等. 腹膜假黏液瘤155例病理预后因素分析[J]. 中华病理学杂志, 2019,48(7):543-549.
[7] Budak E, Kahraman DS, Budak A , et al. The proanostic significance of serum ca125 levels with er, pr, p53 and ki-67 expression in endometrial carcinomas[J]. Ginekol Pol, 2019,90(12):675-683.
[8] 李娜, 李佳娜, 郭丰昌 , 等. 腹膜假性黏液瘤误诊为肝硬化腹水1例报告[J]. 临床肝胆病杂志, 2019,35(5):1079-1080.
[9] 李文忠, 潘妍, 刘佳 , 等. 腹膜假黏液瘤12例临床误诊分析[J]. 临床误诊误治, 2017,30(1):18-20.
[10] Wu JY, Liang CX, Chen MY , et al. Association between tumor-stroma ratio and prognosis in solid tumor patients: A systematic review and meta-analysis[J]. Oncotarget, 2016,7(42):68954-68965.
[11] Peng C, Liu J, Yang G , et al. The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: Proposal of a new tsnm staging system[J]. J Gastroenterol, 2018,53(5):606-617.
[12] 周全, 石峰, 赵洪禹 , 等. 腹膜黏液性肿瘤的临床病理分析[J]. 中华病理学杂志, 2018,47(3):192-195.
[13] Li LT, Jiang G, Chen Q , et al. Ki67 is a promising molecular target in the diagnosis of cancer[J]. Mol Med Rep, 2015,11(3):1566-1572.
[14] Hong B, van den Heuvel APJ, Prabhu VV , et al. Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities[J]. Curr Drug Targets, 2014,15(1):80-89.
[15] Choudry HA, Pai RK, Shuai Y , et al. Impact of cellularity on oncologic outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for pseudomyxoma peritonei[J]. Ann Surg Oncol, 2018,25(1):76-82.
[16] Horvath P, Yurttas C, Birk P , et al. Cellularity in low-grade pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Langenbecks Arch Surg, 2018,403(8):985-990.
[17] Choudry HA , O'Malley ME, Guo ZS, et al.Mucin as a therapeutic target in pseudomyxoma peritonei[J]. J Surg Oncol, 2012,106(7):911-917.
[18] Bhatt A, Mishra S, Prabhu R , et al. Can low grade pmp be divi-ded into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification[J]. Eur J Surg Oncol, 2018,44(7):1105-1111.
[19] Valasek MA, Pai RK . An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms[J]. Adv Anat Pathol, 2018,25(1):38-60.
Outlines

/